[Intraperitoneal chemotherapy for ovarian cancer: a complex strategy but what an exciting avenue!].
نویسنده
چکیده
After more than 20 years of investigation, there are now three (3) major North American phase III trials showing positive results (GOG-172, SWOG-9619, GOG-114/SWOG-9227). Chaired by Dr. Deborah Armstrong, the most recent study, GOG-172, observed an improvement in survival for those women treated with intraperitoneal chemotherapy as adjuvant treatment following optimal cytoreduction surgery for ovarian cancer. This study, along with other published randomized controlled trials, shows a consistent trend of improved survival in a selected group of ovarian cancer patients. The National Cancer Institute in the United States has recently issued a clinical announcement supporting the use of intraperitoneal chemotherapy in this subset of ovarian cancer patients. The Society of Gynecologic Oncologists of Canada (GOC) supports the use of intraperitoneal chemotherapy in optimally debulked stage three ovarian cancer patients. GOC and its partners in comprehensive cancer centres in Canada will develop a strategy to implement this care for our patients.
منابع مشابه
Intraperitoneal chemotherapy in the management of ovarian cancer.
During the past decade, intraperitoneal therapy of ovarian cancer has evolved from a pharmacologic model into an established treatment technique for women with this malignancy. Approximately 40% of patients with small-volume residual ovarian cancer (microscopic disease or macroscopic tumor, < or = 0.5 cm in maximum tumor diameter), after an objective response to initial organoplatinum-based sys...
متن کاملEnhancing the efficacy of cisplatin in ovarian cancer treatment – could arsenic have a role
Ovarian cancer affects more than 200,000 women each year around the world. Most women are not diagnosed until the disease has already metastasized from the ovaries with a resultant poor prognosis. Ovarian cancer is associated with an overall 5 year survival of little more than 50%. The mainstay of front-line therapy is cytoreductive surgery followed by chemotherapy. Traditionally, this has been...
متن کاملTechnique of Post- Operative HIPEC (Hyperthermic Intraperitoneal Chemotherapy) using Veress Needle and IVFluid Warmer In Patients With Epithelial Ovarian Cancer
Objective: Favourable oncological outcomes have been reported with the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer (EOC). However one course of intraoperative HIPEC is complex procedure. We present the simple postoperative technique of HIPEC using Veress needle and IVFluid warmer in patients with ep...
متن کاملHyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
Ovarian cancer remains the fourth leading cause of cancer death in women in France. It is all too often diagnosed at an advanced stage with peritoneal carcinomatosis (PC), but remains confined to the peritoneal cavity throughout much of its natural history. Because of cellular selection pressure over time, most tumor recurrences eventually develop resistance to systemic platinum. Options for sa...
متن کامل99mTc-Glucarate for assessment of paclitaxel therapy in human ovarian cancer in mice
Objectives: The monitoring of cancer treatment response to chemotherapy is considered an essential strategy for follow-up of patients. The aim of this study was to evaluate the use of 99mTc-glucarate as a radiotracer for in vivo quantification and visualization of necrotic area and therapeutic effect of paclitaxel in ovarian cancer xenografted nude mice. Materials and Methods: After implantatio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Bulletin du cancer
دوره 93 9 شماره
صفحات -
تاریخ انتشار 2006